ArticleBMC medical imaging2025
Association of quantitative renal surface nodularity with the renal dysfunction progression in patients with arterial hypertension.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHypertensive nephropathy, a major cause of end-stage renal disease, lacks reliable noninvasive biomarkers. Renal surface nodularity (RSN) on CT may reflect nephrosclerosis, but existing methods fail to quantify nodularity heterogeneity or predict renal decline. This study developed a novel CT-based RSN metric and assessed its prognostic value in hypertensive patients.
methodsThis retrospective cohort study included hypertensive patients who underwent contrast-enhanced CT. Patients with bilateral renal surface irregularities were assigned to the RSN group, with age- (± 2 year) and sex-matched controls (non-RSN group) randomly selected at a 1:1 ratio. RSN was quantified using three surface roughness metrics. A semi-quantitative RSN score was also calculated based on the distribution and depth (> 50% cortical thickness) of localized surface defects. The primary endpoint was composite renal dysfunction progression (≥ 25% eGFR decline or initiation of renal replacement therapy). The secondary endpoint was defined as an annual decline in eGFR > 5 ml/min/1.73 m² per year.
resultsA total of 242 patients were included (median age, 64 years; 70.25% male). Strong linear correlations were observed between quantitative RSN metrics and semi-quantitative score (all ρ > 0.9, P < 0.001). Over a median follow-up of 38.00 months (Interquartile range: 22.00-56.25), patients in the RSN group had a significantly higher risk of renal dysfunction progression (33 vs. 5 events; HR = 5.22, P < 0.001). After adjusting sex, age, hypertension grade, diabetes, hyperlipidemia, eGFR, and renal volume, renal dysfunction progression was independently associated with arithmetic mean deviation (HR = 1.798, 95% CI: 1.296-2.495, P < 0.001), maximum height (HR = 1.606, 95% CI: 1.177-2.191, P = 0.003), and ten-point unevenness height (HR = 2.239, 95%CI: 1.567-3.197, P < 0.001), respectively. The similar statistical results trend was present between RSN and the secondary endpoint.
conclusionsCT-based quantitative RSN was developed as a novel imaging biomarker for renal dysfunction progression in patients with arterial hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.